Egetis Therapeutics AB (LTS:0ABW) FFO


LTS:0ABW Egetis Therapeutics AB LTS:0ABW
59 GF Score
Price kr5.67
GF Value kr5.59
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0ABW
59GF Score
Egetis Therapeutics AB LTS:0ABW
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr5.67 is trading 1.4% above its estimated GF Value™ of kr5.59. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for LTS:0ABW:

  • FFO:
  • GF Value™: kr5.59 vs. price of kr5.67 (1.4% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
59GF Score

Get the complete analysis for LTS:0ABW

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.67
Price
kr5.59
GF Value